Autologous Immunotherapy as a Novel Treatment for Bladder Cancer

摘要: Cancer is fundamentally a disease with failure in regulation tissue growth and the risk of developing cancer increases age. The armamentarium treating mainly threefold: surgical resection tumor, radiation therapy cytotoxic drugs. For blad‐ der cancer, results from contemporary radical cystectomy series pelvic lymph node dis‐ section for T2-4 NX M0 transitional cell carcinoma (TCC) provides accurate pathologic staging primary tumor nodes, due to increasing expertise dif‐ ferent types urinary diversions durable preservation quality life. However, 5year survival rate all patients pT2 tumors approximately 50 – 80%, those negative nodes 64 86% (Stein, Lieskovsky et al. 2001) (Shariat, Karakiewicz 2006) (Hautmann, de Petriconi al.). In contrast, 5-year rates locally ad‐ vanced cancers, pT3 pT4, range 22 58%. presence pathologically proven metastases at associat‐ ed poor outcome 30%.